Oxford Biomedica PLC (OXB.L) stock: key figures, P/E, revenue and dividend

Health Care · United Kingdom · ISIN GB00BDFBVT43

Price
5.32 GBP
Market cap
595.42 m GBP
P/E (2025)
–
P/S (2025)
3.53
Dividend yield
0.00 %
Net margin
-17.85 %
Return on equity (ROE)
-32.98 %
Return on assets (ROA)
-9.25 %

Oxford Biomedica PLC financials

Fiscal year20242025
Revenue128.00 m GBP168.74 m GBP
Gross profit53.00 m GBP65.98 m GBP
Operating income–-29.61 m GBP
EBIT-39.00 m GBP–
Net income-43.00 m GBP-30.13 m GBP
Diluted EPS – continuing operations-0.42 GBP-0.27 GBP

Full history since 1996, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Oxford Biomedica PLC

Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its LentiVector platform technology is a lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems; InAAVate, a proprietary ‘plug and play' dual-plasmid system for transient transfection, as well as a standard triple transfection system for AAV-based gene therapies. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, adenoviral vectors, and other viral vector types. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.